💥 Gate Square Event: #PostToWinCGN 💥
Post original content on Gate Square related to CGN, Launchpool, or CandyDrop, and get a chance to share 1,333 CGN rewards!
📅 Event Period: Oct 24, 2025, 10:00 – Nov 4, 2025, 16:00 UTC
📌 Related Campaigns:
Launchpool 👉 https://www.gate.com/announcements/article/47771
CandyDrop 👉 https://www.gate.com/announcements/article/47763
📌 How to Participate:
1️⃣ Post original content related to CGN or one of the above campaigns (Launchpool / CandyDrop).
2️⃣ Content must be at least 80 words.
3️⃣ Add the hashtag #PostToWinCGN
4️⃣ Include a screenshot s
One-hundred million red: The latest clinical results of the innovative drug deuterated benzbromarone (AR882) for the treatment of gout stones were published at ACR 2025.
Jin10 data reported on October 29th, Yipinhong announced that the latest clinical results of its innovative gout drug deuterated benzbromarone (AR882) for the treatment of gout stones were released at ACR2025 (American College of Rheumatology Annual Meeting). Clinical conclusions show that for patients with newly treated and refractory gout stones, monotherapy with deuterated benzbromarone or combination therapy with allopurinol can effectively drop sUA, reduce urate crystal burden, and achieve a high complete dissolution rate of targeted gout stones. Monotherapy or combination therapy with deuterated benzbromarone can provide a more effective treatment option for patients with chronic gout stones who have poor efficacy with existing treatment regimens.